Compare AbCellera Biologics Inc (ABCL) vs Altria Group Inc (MO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Altria Group Inc — how do they compare? AbCellera Biologics Inc trades at $7.2 (market cap $2.35B), while Altria Group Inc trades at $73.08 (market cap $121.84B). The key difference: Altria Group Inc is far larger — about 51.8× AbCellera Biologics Inc's market cap, and Altria Group Inc pays a 5.81% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | MO | |
|---|---|---|
Market Cap | $2.35B | $121.84B |
Sector | Health | Consumer Staples |
52-Week High | $8.12 | $74.55 |
52-Week Low | $2.78 | $54.72 |
Enterprise Value | $1.99B | $142.91B |
Dividend Yield | — | 5.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
MO trades at $72.96, up 0.34% today, with a bullish technical signal from moving averages and a neutral RSI near 60. The stock shows strong profitability with a 39.52% net margin and consistent cash flow, though revenue has been flat near $20.1B. Analysts are largely positive, with 62% recommending Buy and a consensus target of $70.75. Recent news highlights its appeal as a dividend king for income investors, with a $1.06 dividend paid in July 2026.
Outlook: MO offers stable income with high margins and dividend reliability, but faces risks from debt levels and regulatory pressures. The stock is near analyst targets, suggesting limited upside, yet remains a defensive hold for yield-seeking portfolios amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →
